We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 17, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. (TSLA - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Bank of America Corp. (BAC - Free Report) , QUALCOMM Inc. (QCOM - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Tesla, Eli Lilly and Bank of America
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc., Eli Lilly and Co. and Bank of America Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Tesla have declined -30.4% over the past year against the Zacks Automotive - Domestic industry's decline of -37.7%. The company is facing inflation and macroeconomic concerns which could pose near-term challenges. However, the company's long-term prospects remain solid. The electric vehicle (EV) king is set to benefit from the soaring popularity of its Models 3 and Y.
The Zacks analyst expects deliveries to see an annualized growth of around 33% in 2023. Production ramp-up at gigafactory 4 (in Berlin) and 5 (in Austin) and introduction of new models, including Semi and Cybertruck, are set to support long-term deliveries growth.
Additionally, Tesla's energy generation and storage revenues outlook is promising. Falling debt levels is another positive. We expect Tesla to deliver outsized returns in the long run on the back of output ramp-up and introduction of new models.
Shares of Eli Lilly have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+36.4% vs. +9.6%). The company boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Its revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others.
It is regularly adding promising new pipeline assets through business development deals. Lilly expects to launch four new medicines by 2023 end with Mounjaro for type II diabetes already launched and cancer drug Jaypirca already approved. Mounjaro is off to a solid start.
However, the CRL for donanemab will probably delay the potential launch of the candidate. Generic competition for several drugs, rising pricing pressure in the United States and some international markets are some top-line headwinds.
Bank of America's shares have underperformed the Zacks Banks - Major Regional industry over the past year (-25.5% vs. -17.2%). The company's over-dependence on trading revenues for fee income is concerning. The volatile nature of the capital markets will adversely impact non-interest income performance. Our estimates for the same show a 4.1% fall for 2023. A tough operating backdrop will lead to increase in provisions, with we projecting a substantial jump in the metric this year.
However, higher interest rates and decent loan demand are expected to keep aiding the company's net interest income (NII). Our estimates for NII reflect a CAGR of 10.1% by 2025.
Likewise, the company's net interest yield will continue expanding in the near-term. Also, opening of new financial centers, enhancement in digital capabilities and prudent cost management efforts are expected to keep aiding its financials.
Other noteworthy reports we are featuring today include QUALCOMM Inc. and Gilead Sciences, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences
For Immediate Release
Chicago, IL – February 17, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. (TSLA - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Bank of America Corp. (BAC - Free Report) , QUALCOMM Inc. (QCOM - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Tesla, Eli Lilly and Bank of America
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc., Eli Lilly and Co. and Bank of America Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Tesla have declined -30.4% over the past year against the Zacks Automotive - Domestic industry's decline of -37.7%. The company is facing inflation and macroeconomic concerns which could pose near-term challenges. However, the company's long-term prospects remain solid. The electric vehicle (EV) king is set to benefit from the soaring popularity of its Models 3 and Y.
The Zacks analyst expects deliveries to see an annualized growth of around 33% in 2023. Production ramp-up at gigafactory 4 (in Berlin) and 5 (in Austin) and introduction of new models, including Semi and Cybertruck, are set to support long-term deliveries growth.
Additionally, Tesla's energy generation and storage revenues outlook is promising. Falling debt levels is another positive. We expect Tesla to deliver outsized returns in the long run on the back of output ramp-up and introduction of new models.
(You can read the full research report on Tesla here >>>)
Shares of Eli Lilly have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+36.4% vs. +9.6%). The company boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Its revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others.
It is regularly adding promising new pipeline assets through business development deals. Lilly expects to launch four new medicines by 2023 end with Mounjaro for type II diabetes already launched and cancer drug Jaypirca already approved. Mounjaro is off to a solid start.
However, the CRL for donanemab will probably delay the potential launch of the candidate. Generic competition for several drugs, rising pricing pressure in the United States and some international markets are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
Bank of America's shares have underperformed the Zacks Banks - Major Regional industry over the past year (-25.5% vs. -17.2%). The company's over-dependence on trading revenues for fee income is concerning. The volatile nature of the capital markets will adversely impact non-interest income performance. Our estimates for the same show a 4.1% fall for 2023. A tough operating backdrop will lead to increase in provisions, with we projecting a substantial jump in the metric this year.
However, higher interest rates and decent loan demand are expected to keep aiding the company's net interest income (NII). Our estimates for NII reflect a CAGR of 10.1% by 2025.
Likewise, the company's net interest yield will continue expanding in the near-term. Also, opening of new financial centers, enhancement in digital capabilities and prudent cost management efforts are expected to keep aiding its financials.
(You can read the full research report on Bank of America here >>>)
Other noteworthy reports we are featuring today include QUALCOMM Inc. and Gilead Sciences, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.